Evidence map›Paper›PMID 39271476›Full record

ArticleJNCI cancer spectrum2024

Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer, 2011-2023.

Jenny S Guadamuz, Xiaoliang Wang, Ivy Altomare, Wendy Camelo Castillo, Somnath Sarkar, Ronac Mamtani, Gregory S Calip

Abstract read
In one paragraph

Article in JNCI cancer spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Jenny S GuadamuzFlatiron Health, New York, NY, USA.ORCID 0000-0002-2312-4140
Xiaoliang WangFlatiron Health, New York, NY, USA.ORCID 0000-0001-5184-2935
Ivy AltomareFlatiron Health, New York, NY, USA.ORCID 0000-0002-1222-885X
Wendy Camelo CastilloDepartment of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, USA.ORCID 0000-0003-1336-8106
Somnath SarkarFlatiron Health, New York, NY, USA.
Ronac MamtaniDivision of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-8267-5356
Gregory S CalipFlatiron Health, New York, NY, USA.ORCID 0000-0002-7744-3518

Funding

Flatiron Health, IncRoche Group
6 · The paper itself

Abstract

backgroundAlthough racially and ethnically minoritized populations are less likely to participate in cancer trials, it is unknown whether social determinants of health (SDOH) explain these inequities. Here we identify SDOH factors that contribute to racial and ethnic inequities in clinical trial participation among patients with 22 common cancers.

methodsThis retrospective cohort study used electronic health record data (2011-2023) linked to neighborhood (US Census tract) data from multiple sources. Patients were followed from diagnosis to clinical study drug receipt (proxy for trial participation), death, or last recorded activity. Associations were assessed using Cox proportional hazards models adjusted for clinical factors (year of diagnosis, age, sex, performance status, disease stage, cancer type). To elucidate which area-level SDOH underlie racial and ethnic inequities, mediation analysis was performed using nonlinear multiple additive regression tree models.

resultsThis study included 250 105 patients (64.7% non-Latinx White, 8.9% non-Latinx Black, 5.2% Latinx). Black and Latinx patients were more likely to live in economically or socially marginalized areas (eg, disproportionately minoritized [measure of segregation], limited English proficiency, low vehicle ownership) than White patients. Black (3.7%; hazard ratio = 0.55, 95% confidence interval [CI] = 0.52 to 0.60) and Latinx patients (4.4%; hazard ratio = 0.63, 95% CI = 0.58 to 0.69) were less likely to participate in trials than White patients (6.3%). Fewer patients in economically or socially marginalized neighborhoods participated in trials. Mediators explained 62.2% (95% CI = 49.5% to 74.8%) of participation inequities between Black and White patients; area-level SDOH-including segregation (29.9%, 95% CI = 21.2% to 38.6%) and vehicle ownership (11.6%, 95% CI = 7.0% to 16.1%)-were the most important mediators. Similarly, Latinx-White participation inequities were mediated (65.1%, 95% CI = 49.8% to 80.3%) by area-level SDOH, such as segregation (39.8%, 95% CI = 28.3% to 51.3%), limited English proficiency (11.6%, 95% CI = 2.8% to 20.4%), and vehicle ownership (9.6%, 95% CI = 5.8% to 13.5%).

conclusionsTo improve racial and ethnic diversity in cancer trials, efforts to address barriers related to adverse neighborhood SDOH factors are necessary.

Indexed as

Clinical Trials as TopicNeoplasmsProportional Hazards ModelsSocial Determinants of HealthAdultAgedBlack or African AmericanEthnicityFemaleHealthcare DisparitiesHispanic or LatinoHumansMaleMiddle AgedNeighborhood CharacteristicsPatient Participation

Identifiers

PMID39271476
PMCPMC11495868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.